GlassScriptPhysician profile
Mary Kathryn Mclaughlin
NPI 1558047209
$1,263.98
in general payments reported to CMS, 2019-2025
29 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.00 |
| Education | $139.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $240.30 | 2025 | Octagam Immune Globulin (Human) |
| Janssen Biotech, INC. | $181.87 | 2025 | Rybrevant, Carvykti, Talvey |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $73.94 | 2025 | |
| Merck Sharp & Dohme LLC | $72.37 | 2025 | Keytruda, Welireg, Lynparza |
| Pharmacosmos Therapeutics INC. | $56.90 | 2025 | Monoferric |
| Incyte Corporation | $49.99 | 2025 | |
| Tersera Therapeutics LLC | $47.11 | 2025 | Xermelo |
| Astrazeneca Pharmaceuticals LP | $42.93 | 2025 | Imfinzi |
| Genentech USA, INC. | $39.85 | 2025 | Venclexta, Lunsumio |
| Eisai INC. | $32.52 | 2025 | |
| Lilly USA, LLC | $27.98 | 2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $24.08 | 2025 | Libtayo |
| Astellas Pharma US INC | $23.40 | 2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $23.12 | 2025 | Onivyde |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.00 | 2025 | Datroway |
| Taiho Oncology, INC. | $20.62 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.88 | 2025 | Iclusig |
| Syndax Pharmaceuticals, INC. | $17.85 | 2025 | |
| Aveo Pharmaceuticals, INC. | $16.90 | 2025 | |
| Stemline Therapeutics INC. | $16.67 | 2025 | Elzonris |
| E.R. Squibb & Sons, L.L.C. | $16.55 | 2025 | Opdualag |
| Genzyme Corporation | $16.26 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.99 | 2025 | Pyrukynd |
| Celgene Corporation | $15.95 | 2025 | Reblozyl |
| Pharmaessentia USA Corporation | $15.57 | 2025 | Besremi |
| Boston Scientific Corporation | $15.24 | 2025 | Spaceoar Vue System - 10ml |
| Bayer Healthcare Pharmaceuticals INC. | $14.67 | 2025 | |
| Coherus Oncology, INC. | $14.48 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.